Section
A groundbreaking clinical trial reveals that a novel nasal vaccine, BPZE1, can prevent Bordetella pertussis colonization, offering a potential solution to the transmission gaps in current whooping cough immunization programs.
Large-scale trials in Kenya and Mozambique demonstrate that ivermectin mass drug administration significantly reduces malaria incidence by 26% and lowers community scabies prevalence, providing both direct protection and indirect herd-like
The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, an
The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression
A landmark phase 2a trial in Laos identifies emodepside as a highly effective, weight-independent treatment for Strongyloides stercoralis, achieving cure rates of 89% at a 15 mg dose, matching the current gold standard ivermectin with a rob
GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentiall
The 2023 WHO EGASP study highlights a critical rise in ceftriaxone-resistant gonorrhea in Southeast Asia, with resistance reaching 20% in some regions. These findings underscore the urgent need for enhanced global surveillance and the accel
This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.
The GBD 2023 study highlights a 33.4% reduction in pediatric LRI mortality since 2010, yet 2.5 million annual deaths persist. While Streptococcus pneumoniae remains the primary pathogen, newly modeled aetiologies like non-tuberculous mycoba
A large-scale population-based study in Singapore reveals that acute dengue virus infection is associated with a nearly ten-fold increase in neurological events, including memory loss and movement disorders, particularly in older adults and
A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients su
The MULTI-CAP trial demonstrated that combining multiplex PCR and procalcitonin did not significantly increase the number of antibiotic-free days by Day 28 in ICU patients with pneumonia, although it did successfully reduce the cumulative d
Long-term data from the BArT study and prospective observational trials demonstrate that direct-acting antivirals (DAAs) can achieve 100% viral clearance and durable hematologic responses in HCV-associated indolent lymphomas, potentially re
A global genomic study of Helicobacter pylori reveals that mutations in 23S rRNA and gyrA predict antibiotic resistance with 100% sensitivity, signaling the end of empirical therapy in favor of genotype-based personalized treatment.
The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorab
A 36-week observational study demonstrates that subcutaneous lidocaine-HP-β-CD significantly improves physical and mental quality of life and reduces symptom burden in patients with post-COVID condition, offering a scalable, home-based ther
The RETRO-MENINGO study of 654 adults reveals that hemodynamic presentations of invasive meningococcal disease carry a five-fold higher mortality risk than neurological forms. Early parenteral antibiotic administration remains the most crit
A large-scale multinational study reveals that meropenem and piperacillin dosing during renal replacement therapy must be tailored to RRT intensity and urine output, with extended infusions significantly improving therapeutic target attainm
A large-scale study of over 300,000 ANZ ICU patients reveals that sepsis mortality plummeted from 28% to 11% between 2000 and 2020, followed by a concerning 0.9% annual increase through 2023, highlighting both clinical triumphs and emerging
The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio
